NOVEL FLK-2 AND ANALOGS

Abstract: A purified soluble form of F &cir& _l &cir& _k &cir& _-2 is provided, as the DNA sequence and as the protein. In addition, a partial DNA sequence of the human F &cir& _l &cir& _k &cir& _-2 is also provided. The proteins find use in modulating hematopoiesis in culture and in vivo, as well as for the production of antibodies for assays of the proteins.

Description: NOVEL FLK-2 AND ANALOGS INTRODUCTION Technical Field The field of this invention is the identification and use of hematopoietic factor receptors. Background The process for the development of hematopoietic cells from a self-regenerating stem cell to the mature multi-lineage cells has been the subject of intense investigation. How the host is able to direct a single cell into the multiplicity of pathways which provide such varied cells as lymphocytes, monocytes, macrophages, megakaryocytes and osteoclasts, which is not a complete list, still remains to be elucidated. However, substantial strides have been made in identifying various intermediate cells associated with the different lineages and identifying factors which appear to direct, either by themselves or in combination with other factors, the cells to mature to a particular cell type. For the most part, the factors have been associated with progenitors which are committed to a particular lineage, where the factors result in maturation of the progenitor. Less is known about the factors which direct a totipotent or multipotent cell to be directed to one among many possible lineages . In order to understand the processes of differentiation and maturation, it will be necessary to know which surface membrane proteins act as receptors for transduction of signals, whether they have soluble forms, the role of soluble forms, and which ligands are associated with the surface membrane proteins. It is therefore of substantial interest to be able to identify ligands, receptors and their soluble forms associated with cell regeneration, proliferation, differentiation, and maturation. Relevant Literature Jordan et al . (1990) Cell 81, 953-963 and Matthews et al . (1991) Cell 65:1143-1152 describe isolation of fetal liver stem cells and molecular cloning of FLK-2, a putative stem cell growth factor receptor. Jordan and Lemischka (1990) Genes and Development 4:220-232 describe a clonal and systemic analysis of long-term hematopoiesis in the mouse. Summary of the Invention A soluble form of FLK-2 molecule (SEQ ID NO:3 and SEQ ID NO:4) is provided where the soluble form lacks the transmembrane sequence as well as portions of the extracellular and intra-cellular sequences. In addition, a partial nucleic acid sequence (SEQ ID NO:5) of the gene for human FLK-2 is provided. DESCRIPTION OF THE SPECIFIC EMBODIMENTS Methods and compositions are provided associated with the mammalian regulation of hematopoiesis. Particularly, a soluble form of the mammalian fetal liver kinase-2 (FLK-2) is provided, as well as the human FLK-2. The soluble form of the FLK-2 is characterized by lacking the transmembrane sequence, by being encoded by about a 1.9 kb cDNA, capable of competing with the surface membrane FLK-2 for ligand and having at least 80% homology with the sequence (SEQ ID NO:3) set forth for Flk-2vs in the Experimental section. Substantial sequence conservation of the gene and protein is observed, so that the soluble form may be from primate, particularly human, murine, bovine, ovine, equine, lagomorpha, feline, canine, etc. Nucleic acid encoding Flk-2ws may be obtained from host hematopoietic stem cells by using as a probe, at least twelve, usually at least eighteen, nucleotides of the subject sequence. The subject sequence, which is the mouse sequence, may be used to identify other mammalian analogs by hybridizing under less stringent conditions, e . g. , (1) 6 x SSC, 35°C, 1 hr.; (2) 0.5 x SSC, 35°C, 0.5 hr.; (3) 0.5 x SSC, 50°C, 1 hr., and using Northern blots, dot- blots, or the like. cDNA' s may then be prepared from the mRNA in accordance with known procedures. The cDNA may be used for expression of the Flk-2ws in any convenient expression host, both prokaryotic and eukaryotic hosts. By forming an expression cassette in the direction of transcription of a transcriptional initiation regulatory region, which may or may not include an enhancer, the cDNA or other sequence encoding the same or substantially the same protein, and a transcriptional termination regulatory region, desirably including a polyadenylation signal sequence, the cassette then may be used for introduction into the appropriate host, where the regulatory regions are functional in the host . A wide variety of both prokaryotic and eukaryotic hosts are available, such as E. coli , B . subtilis, yeast, such as S . cerevisiae, Kluyveromyces, fungi, such as proteus, etc., insect cells, mammalian cells, e . g. , COS cells, CHO cells, etc., plant cells, and the like. The particular choice of the host is not critical to this invention, and any host may be employed which allows for the desired expression and, as appropriate, processing. For scientific investigation, the subject composition may be labeled for detection. Various labels include radioisotopes, enzymes, fluorescers, and the like. Methods of labeling a protein are well established in the literature, and need not be exemplified here. The strategy employed for identifying the was to isolate hematopoietic stem cells by separation using long- term cultured w/w hematopoietic stem cells, where the w/w mice lack a functional c-kit gene, the receptor for the steel ligand. The cultured cells were then used for isolation of mRNA, followed by reverse transcription to provide cDNA. Amplification was then achieved using the polymerase chain reaction (PCR) , with primers having homology to the 5' terminal sequence and the sequence 3' of about nucleotide 3400, from about 3400 to about 3430. After separation by 1% agarose gel electrophoresis, two major amplified fragments were cloned, namely a 3.4 and a 1.9 kb DNA fragment. The 3.4 kb DNA fragment represents the native Flk-2 molecule, while the 1.9 kb DNA fragment (SEQ ID NO:3) represents a secreted form of Flk-2, designated Flk-2ws . For isolation of the human, Flk-2, human fetal bone marrow cells were selected for carrying the markers CD 34 + Thy-l + , separation being by any convenient means such as magnetic particles, fluorescence activated cell sorter, panning or the like. Isolated mRNA was used to prepare a cDNA library and mouse Fl- 2ws (SEQ ID NO:3) , or a major portion thereof, may be used as a probe. Stringent conditions were used, employing elevated temperature in the range of about 50 to 65°C, employing a stringency of about 6 x SSC. After cloning in λ phage, positive plaques were selected and re-screened ' and phagemids rescued from the secondary positive λ phage clones. The clones which were obtained lack the 5' end which was obtained by using a portion of the mouse Flk-2 (SEQ ID NO:6) as a probe. The positive clones were then used to provide the 5' end sequence. The human Flk-2 (SEQ ID NO:5) is substantially homologous to the mouse Flk-2 (SEQ ID NO: 6) having the sequence as set forth in the experimental section. It is characterized by being 2.5 kbp. It defines domains analogous to the domains for the mouse membrane bound Flk- 2 and soluble Flk-2. The subject protein may be obtained in purified form, usually at least about 90% pure, preferably at least about 99% pure, as evidenced by a single band in gel electrophoresis. The subject proteins find use in culture and in vivo in competing with Flk-2 receptor for Flk-2 ligand. Thus, the subject compositions may be used for modulating the growth of hematopoietic progenitor cells. In addition, the subject proteins or fragments thereof of at least about 12 amino acids, preferably at least about 18 amino acids, may be used for the production of antibodies, either polyclonal anti- serum or monoclonal antibodies. Particularly, the soluble Flk-2 may be used to produce antibodies which are specific for the juncture or sequences proximal to the juncture between about amino acids 680 and 700, particular at about 690, ±10 amino acids. The antibodies may be used for identifying cells carrying Flk-2, removing soluble Flk-2 from culture fluids or natural fluids, purifying Flk-2, and the like. The antibodies may also be used for assaying for the presence of Flk-2. The following examples are offered by way of illustration and not be way of limitation. EXPERIMENTAL Strategy Long-term cultured w/w stem cells were used as starting material for mRNA isolation. The isolated RNA was used to make cDNA which was then amplified using the polymerase chain reaction with a pair of mouse Flk-2 specific primers. Two DNA fragments migrating at 3.4 and 1.9 kb were identified as the main PCR products. The two DNA fragments were isolated and cloned, and the DNA sequence of the product was identical to the previously reported DNA sequence (Matthews et al . (1991) Proc. Natl . Acad. Sci. USA 88:9026-9030) , while the 1.9 kb DNA fragment represented a secreted soluble Flk-2 molecule (SEQ ID NO:3) , apparently resulting from RNA editing. Isolation of Fetal Liver Cells with Stem Cell Phenotype from w/w Mice Fetal liver cells from newborn w/w mice (Ikuta, K. , et al . (1991) J. Cell Cloning, 9:451-460) were fractionated into Lin + Lin " sub-populations as described previously (Spangrude, G. et al . (1988) Science 241:58-62) . The Lin " population of fetal liver cells was further fractionated into Sca-1 + , Thy-1 + ' Lo by FACS. The resulting Sca-1 + , Thy-1 + ' Lo mouse, Lin " (by FACS) cells were co-cultivated on a monolayer of AC 6.21 (Whitlock, C. et al. (1987) Cell 48:1009-1021) stromal cell line for several weeks. Approximate 1-2% of the long-term culture w/w cells still retained the stem cell phenotype (about 80% of long-term cultured fetal liver cells exhibited B220 positive phenotype) . Isolation of mRNA, cDNA Synthesis PCR Approximately 2 x 10 5 long-term cultured w/w stem cells were collected and used for mRNA isolation. The mRNA was isolated with a Mini-Fast Track in an mRNA isolation kit (Invitrogen) . The mRNA (about 25 ng) from w/w stem cells was primed with oligo dT and reverse-transcribed using avian myeloblastosis virus reverse-transcriptase (BLR) (Maniatis, et al . (1982) Molecular Cloning: A Laboratory Manual) . The synthesized cDNA was purified and dissolved into 20 μl T-buffer (50 mM Tris-HCl pH 8.3 , 50 mM KC1, 10 mM MgCl 2 , 1 mM DDT, 1 mM EDTA, 2 . mM dNTP, 0.5 mM spermidine, 4 mM Na pyrophosphate, 20 pmoles (T) primer) . 4 μl of purified cDNA were amplified using a pair of nested primers specific for mouse Flk-2 : PCLI and PCLII, Perkin-Elmer-Cetus reagents and Perkin-Elmer Thermal Cycler. The primer PCLII is a 24 mer oligonucleotide with the sequence (SEQ ID NO:l) GAGG- CCTGGCTACCGCGCGCTCCG, corresponding to mFlk-2 nucleotide positions 1-24, except that at position 2, C was changed to A. The primer PCLI is a 27 mer oligonucleotide with the sequence (SEQ ID NO:2) ATGGATGGAAATAAACTTTCTACTGTA, corresponding to mFlk-2 nucleotide positions 341 to 3428. The cycle program for the initial amplification was 95°C for 1.5 min. , 55°C for 1 min., and 70°C for 2 min. for a total of 35 cycles. 1 μl of the PCL products from the initial amplification was employed for a second round amplification under the same cycler program. The final PCL products were loaded on a 1% agarose gel. There were two major PCR amplified DNA fragments migrating at 3.4 and 1.9 kb. Molecular Cloning FlJ -2ws and DNA Sequencing The 3.4 and 1.9 kb DNA fragments which were fractions of the 1% TAE agarose gel were isolated dependently by the Nal-glass bead method (Gene Clean, BIO101) then cloned into pCRlOOO vector at the HphI site. Restriction mapping was carried out on the individual clones, with both cDNA inserts hybridizing equally well to the 32 P-label oligo primers specific to mFlk-2, indicating a close relationship between the 1.9 kb cDNA and the 3.4 mFlk-2 molecule. In order to confirm the relationship, both 1.9 and 3.4 kb inserts were sequenced. The cloned cDNA inserts were sequenced by the dideoxy method of Sanger by using double stranded templates Sequenase II (USB) , α- 35 S [dATP] (Amersham) and series primers as synthesized according to the mFlk-2 DNA sequence. A comparison of the sequences demonstrated that the 3.4 kb cDNA had the identical DNA sequence to the published mFlk-2, and the 1.9 kb cDNA was an alternative spliced form of the mFlk-2 molecule. The difference was a 1.5 kb internal deletion by differential splicing. There is a 511 amino acid deletion beginning with the amino acid 221 Val and ending with the 721 Gin, so that the Lys at 220 is joined to the Ala at 732. The 1.9 kb cDNA is designated as mFlk-2vrs . The DNA (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequence of Flk-2ws as well as a partial sequence (SEQ ID NO:6) of the human Flk-2 compared to the mouse sequence are provided. Human Flk-2 (hu Flk-2) Strategy The mRNA from 3 x 10 5 Thy-1 + CD34 + human fetal bone marrow cells is used to construct a cDNA library in Uni-Zip λ (Strategene) . Approximately 10 5 phage plaques from the cDNA library are transferred onto nitrocellulose filters and are screened with 32 P-labeled full length mFlk- 2ws as a probe. The hybridization condition is 60°C, 12 hours in 6 x SSC 0.5% dry milk, 1 mM EDTA and 0.02% sodium azide. The hybridized filters are washed twice with 6 x SSC at room temperature for 10 min., 3 times with 0.5 x SSC and 0.1% SSC at room temperature for 10 min. Positive plaques are picked and re-screened with 32 P-labeled probe. Phagemids are rescued from the secondary positive λ phage clones, the cDNA inserts evaluated by Southern blots with the same probe as above. The cDNA inserts are then screened for size and partial DNA sequences taken to establish their relationship to the mFlk-2v ~ s . It is evident from the above results, that a novel soluble form of Flk-2 is provided, which finds use in investigating hematopoiesis, competing with the surface membrane bound Flk-2 for ligand, producing antibodies for assaying for the presence of Flk-2 , either on the surface of cells or in a medium, and in culture and in therapy in association with the modulation of hematopoiesis. Also, the human surface membrane bound Flk-2 may be used in analogous ways and may further be used employing recombinant techniques to fuse various domains of Flk-2 to domains of other proteins to provide novel fused proteins for novel properties associated with the two domains . SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: YANG, Zhi (ii) TITLE OF INVENTION: NOVEL FLK-2 AND ANALOGS (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Bertram I . Rowland (B) STREET: 4 Embarcadero Center, Suite 3400 (C) CITY: San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94111 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US93/ (B) FILING DATE: 07-JUL-1993 (C) CLASSIFICATION: 435 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Rowland, Bertram I. (B) REGISTRATION NUMBER: 20,015 (C) REFERENCE/DOCKET NUMBER: FP-55931/BIR (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (415)789-1989 (B) TELEFAX: (415) 398-3249 (2) INFORMATION FOR SEQ ID NO:1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 GAGGCCTGGC TACCGCGCGC TCCG 24 (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 ATGGATGGAA ATAAACTTTC TACTGTA 27 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1894 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 31..1473 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : GCGGCCTGGC TACCGCGCGC TCCGGAGGCC ATG CGG GCC TTG GCG CAG CGC AGC 54 Met Arg Ala Leu Ala Gin Arg Ser GAC CGG CGG CTG CTG CTG CTT GTT GTT TTG TCA GTA ATG ATT CTT GAG 102 Asp Arg Arg Leu Leu Leu Leu Val Val Leu Ser Val Met lie Leu Glu 10 15 20 ACC GTT ACA AAC CAA GAC CTG CCT GTG ATC AAG TGT GTT TTA ATC AGT 150 Thr Val Thr Asn Gin Asp Leu Pro Val lie Lys Cys Val Leu lie Ser 25 30 35 40 CAT GAG AAC AAT GGC TCA TCA GCG GGA AAG CCA TCA TCG TAC CGA ATG 198 His Glu Asn Asn Gly Ser Ser Ala Gly Lys Pro Ser Ser Tyr Arg Met 45 50 55 GTG CGA GGA TCC CCA GAA GAC CTC CAG TGT ACC CCG AGG CGC CAG AGT 246 Val Arg Gly Ser Pro Glu Asp Leu Gin Cys Thr Pro Arg Arg Gin Ser 60 65 70 GAA GGG ACG GTA TAT GAA GCG GCC ACC GTG GAG GTG GCC GAG TCT GGG 294 Glu Gly Thr Val Tyr Glu Ala Ala Thr Val Glu Val Ala Glu Ser Gly 75 80 85 TCC ATC ACC CTG CAA GTG CAG CTC GCC ACC CCA GGG GAC CTT TCC TGC 342 Ser lie Thr Leu Gin Val Gin Leu Ala Thr Pro Gly Asp Leu Ser Cys 90 95 100 CTC TGG GTC TTT AAG CAC AGC TCC CTG GGC TGC CAG CCG CAC TTT GAT 390 Leu Trp Val Phe Lys His Ser Ser Leu Gly Cys Gin Pro His Phe Asp 105 110 115 120 TTA CAA AAC AGA GGA ATC GTT TCC ATG GCC ATC TTG AAC GTG ACA GAG 438 Leu Gin Asn Arg Gly lie Val Ser Met Ala lie Leu Asn Val Thr Glu 125 130 135 ACC CAG GCA GGA GAA TAC CTA CTC CAT ATT CAG AGC GAA CGC GCC AAC 486 Thr Gin Ala Gly Glu Tyr Leu Leu His lie Gin Ser Glu Arg Ala Asn 140 145 150 TAC ACA GTA CTG TTC ACA GTG AAT GTA AGA GAT ACA CAG CTG TAT GTG 534 Tyr Thr Val Leu Phe Thr Val Asn Val Arg Asp Thr Gin Leu Tyr Val 155 160 165 CTA AGG AGA CCT TAC TTT AGG AAG ATG GAA AAC CAG GAT GCA CTG CTC 582 Leu Arg Arg Pro Tyr Phe Arg Lys Met Glu Asn Gin Asp Ala Leu Leu 170 175 180 TGC ATC TCC GAG GGT GTT CCG GAG CCC ACT GTG GAG TGG GTG CTC TGC 630 Cys lie Ser Glu Gly Val Pro Glu Pro Thr Val Glu Trp Val Leu Cys 185 190 195 200 AGC TCC CAC AGG GAA AGC TGT AAA GAA GAA GGC CCT GCT GTT GTC AGA 678 Ser Ser His Arg Glu Ser Cys Lys Glu Glu Gly Pro Ala Val Val Arg 205 210 215 AAG GAG GAA AAG GCA CAT TCA AAT TCC AGC ATG CCT GGT TCA CGA GAA 726 Lys Glu Glu Lys Ala His Ser Asn Ser Ser Met Pro Gly Ser Arg Glu 220 225 230 GTT CAG TTA CAC CCG CCC TTG GAT CAG CTC TCA GGG TTC AAT GGG AAT 774 Val Gin Leu His Pro Pro Leu Asp Gin Leu Ser Gly Phe Asn Gly Asn 235 240 245 TCA ATT CAT TCT GAA GAT GAG ATT GAA TAT GAA AAC CAG AAG AGG CTG 822 Ser lie His Ser Glu Asp Glu lie Glu Tyr Glu Asn Gin Lys Arg Leu 250 255 260 GCA GAA GAA GAG GAG GAA GAT TTG AAC GTG CTG ACG TTT GAA GAC CTC 870 Ala Glu Glu Glu Glu Glu Asp Leu Asn Val Leu Thr Phe Glu Asp Leu 265 270 275 280 CTT TGC TTT GCG TAC CAA GTG GCC AAA GGC ATG GAA TTC CTG GAG TTC 918 Leu Cys Phe Ala Tyr Gin Val Ala Lys Gly Met Glu Phe Leu Glu Phe 285 290 295 AAG TCG TGT GTC CAC AGA GAC CTG GCA GCC AGG AAT GTG TTG GTC ACC 966 Lys Ser Cys Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr 300 305 310 CAC GGG AAG GTG GTG AAG ATC TGT GAC TTT GGA CTG GCC CGA GAC ATC 1014 His Gly Lys Val Val Lys lie Cys Asp Phe Gly Leu Ala Arg Asp lie 315 320 325 CTG AGC GAC TCC AGC TAC GTC GTC AGG GGC AAC GCA CGG CTG CCG GTG 1062 Leu Ser Asp Ser Ser Tyr Val Val Arg Gly Asn Ala Arg Leu Pro Val 330 335 340 AAG TGG ATG GCA CCC GAG AGC TTA TTT GAA GGG ATC TAC ACA ATC AAG 1110 Lys Trp Met Ala Pro Glu Ser Leu Phe Glu Gly lie Tyr Thr lie Lys 345 350 355 360 AGT GAC GTC TGG TCC TAC GGC ATC CTT CTC TGG GAG ATA TTT TCA CTG 1158 Ser Asp Val Trp Ser Tyr Gly lie Leu Leu Trp Glu lie Phe Ser Leu 365 370 375 GGT GTG AAC CCT TAC CCT GGC ATT CCT GTC GAC GCT AAC TTC TAT AAA 1206 Gly Val Asn Pro Tyr Pro Gly lie Pro Val Asp Ala Asn Phe Tyr Lys 380 385 390 CTG ATT CAG AGT GGA TTT AAA ATG GAG CAG CCA TTC TAT GCC ACA GAA 1254 Leu lie Gin Ser Giy Phe Lys Met Glu Gin Pro Phe Tyr Ala Thr Glu 395 400 405 GGG ATA TAC TTT GTA ATG CAA TCC TGC TGG GCT TTT GAC TCA AGG AAG 1302 Gly lie Tyr Phe Val Met Gin Ser Cys Trp Ala Phe Asp Ser Arg Lys 410 415 420 CGG CCA TCC TTC CCC AAC CTG ACT TCA TTT TTA GGA TGT CAG CTG GCA 1350 Arg Pro Ser Phe Pro Asn Leu Thr Ser Phe Leu Gly Cys Gin Leu Ala 425 430 435 440 GAG GCA GAA GAA GCA TGT ATC AGA ACA TCC ATC CAT CTA CCA AAA CAG 1398 Glu Ala Glu Glu Ala Cys lie Arg Thr Ser lie His Leu Pro Lys Gin 445 450 455 GCG GCC CCT CAG CAG AGA GGC GGG CTC AGA GCC CAG TCG CCA CAG CGC 1446 Ala Ala Pro Gin Gin Arg Gly Gly Leu Arg Ala Gin Ser Pro Gin Arg 460 465 470 CAG GTG AAG ATT CAC AGA GAA AGA AGT TAGCGAGGAG GCCTTGGACC 1493 Gin Val Lys lie His Arg Glu Arg Ser 475 480 CCGCCACCCT AGCAGGCTGT AGACCGCAGA GCCAAGATTA GCCTCGCCTC TGAGGAAGCG 1553 CCCTACAGCG CGTTGCTTCG CTGGACTTTT CTCTAGATGC TGTCTGCCAT TACTCCAAAG 1613 TGACTTCTAT AAAATCAAAC CTCTCCTCGC ACAGGCGGGA GAGCCAATAA TGAGACTTGT 1673 TGGTGAGCCC GCCTACCCTG GGGGCCTTTC CACGAGCTTG AGGGGAAAGC CATGTATCTG 1733 AAATATAGTA TATTCTTGTA AATACGTGAA ACAAACCAAA CCCGTTTTTT GCTAAGGGAA 1793 AGCTAAATAT GATTTTTAAA AATCTATGTT TTAAAATACT ATGTAACTTT TTCATCTATT 1853 TAGTGATATA TTTTATGGAT GGAAATAAAC TTTCTACTGT A 1894 (2) INFORMATION FOR SEQ ID NO:4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 481 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : Met Arg Ala Leu Ala Gin Arg Ser Asp Arg Arg Leu Leu Leu Leu Val 1 5 10 15 Val Leu Ser Val Met lie Leu Glu Thr Val Thr Asn Gin Asp Leu Pro 20 25 30 Val lie Lys Cys Val Leu lie Ser His Glu Asn Asn Gly Ser Ser Ala 35 40 45 Gly Lys Pro Ser Ser Tyr Arg Met Val Arg Gly Ser Pro Glu Asp Leu 50 55 60 Gin Cys Thr Pro Arg Arg Gin Ser Glu Gly Thr Val Tyr Glu Ala Ala 65 70 75 80 Thr Val Glu Val Ala Glu Ser Gly Ser lie Thr Leu Gin Val Gin Leu 85 90 95 Ala Thr Pro Gly Asp Leu Ser Cys Leu Trp Val Phe Lys His Ser Ser 100 105 110 Leu Gly Cys Gin Pro His Phe Asp Leu Gin Asn Arg Gly lie Val Ser 115 120 125 Met Ala lie Leu Asn Val Thr Glu Thr Gin Ala Gly Glu Tyr Leu Leu 130 135 140 His lie Gin Ser Glu Arg Ala Asn Tyr Thr Val Leu Phe Thr Val Asn 145 150 155 160 Val Arg Asp Thr Gin Leu Tyr Val Leu Arg Arg Pro Tyr Phe Arg Lys 165 170 175 Met Glu Asn Gin Asp Ala Leu Leu Cys lie Ser Glu Gly Val Pro Glu 180 185 190 Pro Thr Val Glu Trp Val Leu Cys Ser Ser His Arg Glu Ser Cys Lys 195 200 205 Glu Glu Gly Pro Ala Val Val Arg Lys Glu Glu Lys Ala His Ser Asn 210 215 220 Ser Ser Met Pro Gly Ser Arg Glu Val Gin Leu His Pro Pro Leu Asp 225 230 235 240 Gin Leu Ser Gly Phe Asn Gly Asn Ser lie His Ser Glu Asp Glu lie 245 250 255 Glu Tyr Glu Asn Gin Lys Arg Leu Ala Glu Glu Glu Glu Glu Asp Leu 260 265 270 Asn Val Leu Thr Phe Glu Asp Leu Leu Cys Phe Ala Tyr Gin Val Ala 275 280 285 Lys Gly Met Glu Phe Leu Glu Phe Lys Ser Cys Val His Arg Asp Leu 290 295 300 Ala Ala Arg Asn Val Leu Val Thr His Gly Lys Val Val Lys lie Cys 305 310 315 320 Asp Phe Gly Leu Ala Arg Asp lie Leu Ser Asp Ser Ser Tyr Val Val 325 330 335 Arg Gly Asn Ala Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ser Leu 340 345 350 Phe Glu Gly lie Tyr Thr lie Lys Ser Asp Val Trp Ser Tyr Gly lie 355 360 365 Leu Leu Trp Glu lie Phe Ser Leu Gly Val Asn Pro Tyr Pro Gly lie 370 375 380 Pro Val Asp Ala Asn Phe Tyr Lys Leu lie Gin Ser Gly Phe Lys Met 385 390 395 400 Glu Gin Pro Phe Tyr Ala Thr Glu Gly lie Tyr Phe Val Met Gin Ser 405 410 415 Cys Trp Ala Phe Asp Ser Arg Lys Arg Pro Ser Phe Pro Asn Leu Thr 420 425 430 Ser Phe Leu Gly Cys Gin Leu Ala Glu Ala Glu Glu Ala Cys lie Arg 435 440 445 Thr Ser lie His Leu Pro Lys Gin Ala Ala Pro Gin Gin Arg Gly Gly 450 455 460 Leu Arg Ala Gin Ser Pro Gin Arg Gin Val Lys lie His Arg Glu Arg 465 470 475 480 Ser (2) INFORMATION FOR SEQ ID NO:5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 146 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 : AATAAAAAGG CTAACAGAAA AGTGTTTGGC CAGTGGGTGT CGAGCAGTAC TCTAAATATG 60 AGTGAGGCCG GGAAAGGGCT TCTGGTCAAA TGCTGTGCGT ACAATTCTAT GGGCACGTCT 120 TGCGAAACCA TCTTTTTAAA CTCACC 146 (2) INFORMATION FOR SEQ ID NO:6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 151 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6 : CTGGAATAGA AAGGCTAACA GAAAAGTGTT TGGACAGTGG GTGTCGAGCA GTACTCTAAA 60 CATGAGTGAA GCCATAAAAG GGTTCTGGTC AAGTGCTGTG ACTACAATTC CCTTGGCACA 120 TCTGTGAGAG CATCCTTTTA AACTCTACCG G 151

Claims: WHAT IS CLAIMED IS: 1. A cDNA sequence (SEQ ID NO:3) encoding soluble Flk-2. 2. An expression cassette comprising a cDNA sequence (SEQ ID NO:3) encoding soluble Flk-2 joined to and under the regulation of a transcriptional and translational regulatory region. 3. A vector comprising the expression cassette according to Claim 2. 4. A method of producing soluble Flk-2 (SEQ ID NO:4) , said method comprising: growing a cell comprising an expression cassette according to Claim 2, wherein said regulatory region is functional in said cell; whereby soluble Flk-2 (SEQ ID NO:4) is expressed. 5. A method of inhibiting binding of the Flk-2 ligand to Flk-2, said method comprising: combining said ligand with soluble Flk-2 (SEQ ID NO:4) . 6. A method of modulating the growth of hematopoietic progenitor cells which utilize steel factor for regulation, said method comprising: combining said cells with soluble Flk-2 (SEQ ID NO:4) . 7. Soluble Flk-2 (SEQ ID NO:4) as a purified composition. 8. Substantially pure soluble Flk-2 (SEQ ID NO:4) according to Claim 7. 9. A cDNA encoding human Flk-2 (SEQ ID NO:5) . 10. An expression cassette comprising a cDNA sequence encoding human Flk-2 (SEQ ID NO:5) joined to and under the regulation of a transcriptional and translational regulatory region. 11. A vector comprising the expression cassette according to Claim 10. 12. A method of producing human Flk-2 (SEQ ID NO:5) , said method comprising: growing a cell comprising an expression cassette according to Claim 2, wherein said regulatory region is functional in said cell; whereby human Flk-2 (SEQ ID NO:5) is expressed.

Inventors: YANG ZHI, YANG, ZHI
Applicants: SYSTEMIX INC, SYSTEMIX, INC.
Application year: 1993
Main classification: C12P21
IPC codes: A61K38, C07K14